Immune Infiltration Pattern Associated with Diagnosis and Development in benign Prostatic Hyperplasia
Urology Journal,
Vol. 18 No. 05 (2021),
7 November 2021
,
Page 564-572
https://doi.org/10.22037/uj.v18i05.6678
Abstract
Purpose: Benign prostatic hyperplasia (BPH) significantly reduces the quality of life. However, the biological mechanisms of BPH development remain largely unknown. We aimed to investigate the essential genomic and immunogenic features in BPH.
Materials and Methods: Transcriptome profiling and clinical data of BPH and normal prostate samples were acquired from GEO datasets. The discovery sets were composed of GSE119195, GSE7307, GSE101486, while validation set was GSE132714. ESTIMATE and CIBERSORT was used to investigate the immunogenic features. Furthermore, transcriptional and weighted gene co-expression network analysis (WGCNA) was used for further analysis.
Results: BPH samples presented higher immune score. Meanwhile, CIBERSORT deconvolution revealed that BPH exists significantly abundant M2 Macrophages, follicular T helper cells, resting mast cells, and fewer plasma cells, activated CD4+ memory T cells and activated mast cells. WGCNA analysis also revealed significantly enriched immune-related modules in BPH. Transcriptomic analysis identified SOCS3, IL6, C3, IGF1, NOTCH1 and VCAN as key regulators of immunogenic phenotype in BPH. Moreover, we generated an immunological gene signature for BPH, which worked well in validation cohort.
Conclusion: In our study, BPH samples exhibited a distinct immune infiltration pattern, represented by an immunological gene signature. This genomic-based assessment model reveals the potential transcriptomic patterns during BPH development.
- benign prostatic hyperplasia
- transcriptomics
- immune cell infiltration
- diagnostic biomarker
How to Cite
References
2. Vignozzi L, Gacci M and Maggi M. Lower urinary tract symptoms, benign prostatic hyperplasia and metabolic syndrome. Nat Rev Urol 2016; 13: 108-119. 2016/01/13. DOI: 10.1038/nrurol.2015.301.
3. Gacci M, Andersson KE, Chapple C, et al. Latest Evidence on the Use of Phosphodiesterase Type 5 Inhibitors for the Treatment of Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia. Eur Urol 2016; 70: 124-133. 2016/01/26. DOI: 10.1016/j.eururo.2015.12.048.
4. Kim EH, Larson JA and Andriole GL. Management of Benign Prostatic Hyperplasia. Annu Rev Med 2016; 67: 137-151. 2015/09/04. DOI: 10.1146/annurev-med-063014-123902.
5. Elzayat EA and Elhilali MM. Holmium laser enucleation of the prostate (HoLEP): long-term results, reoperation rate, and possible impact of the learning curve. Eur Urol 2007; 52: 1465-1471. 2007/05/15. DOI: 10.1016/j.eururo.2007.04.074.
6. Lee KL and Peehl DM. Molecular and cellular pathogenesis of benign prostatic hyperplasia. J Urol 2004; 172: 1784-1791. 2004/11/16. DOI: 10.1097/01.ju.0000133655.71782.14.
7. Cunha GR, Donjacour AA, Cooke PS, et al. The endocrinology and developmental biology of the prostate. Endocr Rev 1987; 8: 338-362. 1987/08/01. DOI: 10.1210/edrv-8-3-338.
8. De Nunzio C, Presicce F and Tubaro A. Inflammatory mediators in the development and progression of benign prostatic hyperplasia. Nat Rev Urol 2016; 13: 613-626. 2016/10/01. DOI: 10.1038/nrurol.2016.168.
9. Bostanci Y, Kazzazi A, Momtahen S, et al. Correlation between benign prostatic hyperplasia and inflammation. Curr Opin Urol 2013; 23: 5-10. 2012/11/20. DOI: 10.1097/MOU.0b013e32835abd4a.
10. Gharaee-Kermani M, Kasina S, Moore BB, et al. CXC-type chemokines promote myofibroblast phenoconversion and prostatic fibrosis. PLoS One 2012; 7: e49278. 2012/11/23. DOI: 10.1371/journal.pone.0049278.
11. Rodriguez-Nieves JA, Patalano SC, Almanza D, et al. CXCL12/CXCR4 Axis Activation Mediates Prostate Myofibroblast Phenoconversion through Non-Canonical EGFR/MEK/ERK Signaling. PLoS One 2016; 11: e0159490. 2016/07/21. DOI: 10.1371/journal.pone.0159490.
12. Luo J, Dunn T, Ewing C, et al. Gene expression signature of benign prostatic hyperplasia revealed by cDNA microarray analysis. Prostate 2002; 51: 189-200. 2002/04/23. DOI: 10.1002/pros.10087.
13. Prakash K, Pirozzi G, Elashoff M, et al. Symptomatic and asymptomatic benign prostatic hyperplasia: molecular differentiation by using microarrays. Proc Natl Acad Sci U S A 2002; 99: 7598-7603. 2002/05/29. DOI: 10.1073/pnas.112191399.
14. Liu D, Shoag JE, Poliak D, et al. Integrative multiplatform molecular profiling of benign prostatic hyperplasia identifies distinct subtypes. Nat Commun 2020; 11: 1987. 2020/04/26. DOI: 10.1038/s41467-020-15913-6.
15. Middleton LW, Shen Z, Varma S, et al. Genomic analysis of benign prostatic hyperplasia implicates cellular re-landscaping in disease pathogenesis. JCI Insight 2019; 5 2019/05/17. DOI: 10.1172/jci.insight.129749.
16. Xiao H, Jiang Y, He W, et al. Identification and functional activity of matrix-remodeling associated 5 (MXRA5) in benign hyperplastic prostate. Aging (Albany NY) 2020; 12: 8605-8621. 2020/05/12. DOI: 10.18632/aging.103175.
17. Leek JT, Johnson WE, Parker HS, et al. The sva package for removing batch effects and other unwanted variation in high-throughput experiments. Bioinformatics 2012; 28: 882-883. 2012/01/20. DOI: 10.1093/bioinformatics/bts034.
18. Yoshihara K, Shahmoradgoli M, Martinez E, et al. Inferring tumour purity and stromal and immune cell admixture from expression data. Nat Commun 2013; 4: 2612. 2013/10/12. DOI: 10.1038/ncomms3612.
19. Newman AM, Liu CL, Green MR, et al. Robust enumeration of cell subsets from tissue expression profiles. Nat Methods 2015; 12: 453-457. 2015/03/31. DOI: 10.1038/nmeth.3337.
20. Langfelder P and Horvath S. WGCNA: an R package for weighted correlation network analysis. BMC Bioinformatics 2008; 9: 559. 2008/12/31. DOI: 10.1186/1471-2105-9-559.
21. Ritchie ME, Phipson B, Wu D, et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res 2015; 43: e47. 2015/01/22. DOI: 10.1093/nar/gkv007.
22. Bardan R, Dumache R, Dema A, et al. The role of prostatic inflammation biomarkers in the diagnosis of prostate diseases. Clin Biochem 2014; 47: 909-915. 2014/02/25. DOI: 10.1016/j.clinbiochem.2014.02.008.
23. Papadoukakis S, Kyroudi-Voulgari A, Truss MC, et al. Quantitative study of mast cells in experimentally induced benign prostatic hyperplasia. Urol Int 2010; 84: 100-104. 2010/02/23. DOI: 10.1159/000273475.
24. Ou Z, He Y, Qi L, et al. Infiltrating mast cells enhance benign prostatic hyperplasia through IL-6/STAT3/Cyclin D1 signals. Oncotarget 2017; 8: 59156-59164. 2017/09/25. DOI: 10.18632/oncotarget.19465.
25. Kramer G, Mitteregger D and Marberger M. Is benign prostatic hyperplasia (BPH) an immune inflammatory disease? Eur Urol 2007; 51: 1202-1216. 2006/12/22. DOI: 10.1016/j.eururo.2006.12.011.
26. De Nunzio C, Kramer G, Marberger M, et al. The controversial relationship between benign prostatic hyperplasia and prostate cancer: the role of inflammation. Eur Urol 2011; 60: 106-117. 2011/04/19. DOI: 10.1016/j.eururo.2011.03.055.
27. Vignozzi L, Gacci M, Cellai I, et al. Fat boosts, while androgen receptor activation counteracts, BPH-associated prostate inflammation. Prostate 2013; 73: 789-800. 2013/04/27. DOI: 10.1002/pros.22623.
28. Mosli HA, Al-Abd AM, El-Shaer MA, et al. Local inflammation influences oestrogen metabolism in prostatic tissue. BJU Int 2012; 110: 274-282. 2011/12/08. DOI: 10.1111/j.1464-410X.2011.10796.x.
- Abstract Viewed: 177 times
- 6678/pdf Downloaded: 149 times